Eton Pharmaceuticals, Inc. Construction in Progress, Gross
Eton Pharmaceuticals, Inc. (ETON) had Construction in Progress, Gross of $0 as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization › Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization
us-gaap:ConstructionInProgressGross · last filed 2024-11-12
- 2024-09-30: Construction in Progress, Gross $0.00.
- 2024-06-30: Construction in Progress, Gross $0.00.
- 2024-03-31: Construction in Progress, Gross $0.00.
- 2023-12-31: Construction in Progress, Gross $0.00.
| Period end | Construction in Progress, Gross |
|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 |
| 2023-12-31 | $0.00 10-Q · filed 2024-11-12 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 |
| 2022-12-31 | $12.00K 10-K · filed 2024-03-14 |
| 2022-03-31 | $12.00K 10-Q · filed 2023-05-11 |
| 2020-09-30 | $1.00K 10-Q · filed 2020-11-12 |
| 2020-03-31 | $4.00K 10-Q · filed 2020-05-14 |
| 2019-12-31 | $9.00K 10-K · filed 2021-03-16 |
| 2019-09-30 | $3.00K 10-Q · filed 2019-11-14 |
| 2019-03-31 | $873.00K 10-Q · filed 2019-05-07 |
| 2018-12-31 | $492.00K 10-K · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |